Reproxalap PDUFA Delay, FDA Call & AbbVie Option (Dec 2025 Regulatory Update)

1. Executive Snapshot

Key event On December 16, 2025, the FDA formally extended the PDUFA target action date for reproxalap in dry eye disease from December 16, 2025 to March 16, 2026, after Aldeyra submitted the Clinical Study Report (CSR) for its dry-eye field trial to the NDA at the FDA’s request.

Why the delay The CSR had already been reviewed under the IND; the extension is driven by a “major amendment” classification (moving that CSR formally into the NDA), not by a brand-new efficacy or safety requirement.

Initial reaction The stock opened the day with a sharp gap down (around high single to low double-digit percentage loss in pre-market) on the headline “PDUFA delay”, before buyers stepped in and intraday trading turned into a high-volume tug-of-war.

Quietly positive detail Before the extension, the FDA had already sent Aldeyra a draft label for reproxalap; Aldeyra has responded with comments. In the extension notice, FDA wrote that, if no major deficiencies are identified, it expects to communicate labeling requests and potential post-marketing requirements by February 16, 2026.

In practical terms: the review is described as “substantively complete” by the division. The delay looks like file-completeness housekeeping initiated by the Office of Specialty Medicine, not a sudden shift in the data package itself.

3. Inside the December 12 FDA discussion and the conference call

3.1. Timeline to the extension

• June 16, 2025 – Aldeyra resubmits the reproxalap NDA in dry eye disease.
• July 16, 2025 – FDA accepts the resubmission as a “complete Class II response”, setting the PDUFA date at December 16, 2025.
• Early December 2025 – FDA sends Aldeyra a draft label; Aldeyra responds with comments.
• December 12, 2025 – In a meeting with the Division of Ophthalmology, Aldeyra is told that the Office of Specialty Medicine (the signatory office, above the division) wants the field trial CSR formally submitted into the NDA.
• December 16, 2025 – FDA issues the formal notice of a 90-day PDUFA extension, with a new target action date of March 16, 2026.

On the call, CEO Todd Brady emphasized that before resubmitting the NDA in June, Aldeyra had discussed both the positive dry-eye chamber trial and the field trial with the FDA. At that time:

• The field trial was known to be supportive vs vehicle but did not meet its primary symptom endpoint.
• The division agreed in writing that Aldeyra could submit the chamber trial alone to address the Complete Response Letter.

What changed is not the data; it is the internal reading of protocol at the Office of Specialty Medicine: all completed trials should sit inside the NDA, even if they have already been reviewed under the IND.

3.2. What FDA flagged (and did not flag)

• The Division of Ophthalmology told Aldeyra that, in their view, the review is substantively complete, including its prior review of the field trial under the IND.
• At the December 12 meeting, the division made no additional specific requests beyond the CSR inclusion.
• FDA’s extension letter states that if no major deficiencies are identified, labeling requests and potential post-marketing requirements will be communicated by February 16, 2026.

In other words: the delay is not framed as “we don’t believe the data”. It is framed as “put all the data in the right file, then we finish the paperwork”.

5. Cash, burn and runway

The latest detailed view comes from the Form 10-Q for the quarter ended September 30, 2025. Numbers below are rounded.

• Cash and cash equivalents: approximately 59.3M USD.
• Marketable securities: approximately 16.0M USD.
• Total cash and securities: about 77.5M USD.
• Total liabilities: around 28.6M USD, including roughly 15.2M USD in current debt and about 6.0M USD in deferred collaboration revenue (linked to the AbbVie agreement).
• Shareholders’ equity: about 49.2M USD.

On the P&L side for the first nine months of 2025:

• Net loss: approximately 27.4M USD, a clear improvement versus roughly 40.0M USD in the same period of 2024.
• R&D + G&A: about 28.6M USD combined, down from roughly 43.5M USD in the prior-year period.

This points to a company that has already shifted into a lean pre-launch posture. At that burn rate, ~77.5M USD in cash and securities translates into roughly two years of runway under current conditions, before considering any commercial-launch spend or potential AbbVie inflows.

As always, runway estimates are highly sensitive to strategic choices (launch intensity, pipeline spend) and to the outcome of the reproxalap decision. A negative outcome or a prolonged stalemate would likely bring financing risk back into focus.

7. Sentiment — how the market is digesting the delay

The delay landed exactly where sentiment is most sensitive: regulated, binary biotech with a big-pharma option on the table. The reaction across trading communities and patient forums is noisy but revealing.

7.1. Trading tape and message flow

• The PDUFA extension headline immediately pushed ALDX into the list of most-discussed tickers on real-time platforms such as Stocktwits.
• Message volume and intraday range both surged, consistent with a classic “gap down on headline, then violent tug-of-war between buyers and sellers”.

7.2. Recurring themes in trader commentary

A rough map of the crowd:

• Constructive camp — stresses that:
  • The field trial CSR was already reviewed; moving it into the NDA is bureaucracy, not a data reset.
  • Labeling discussions only happen when a drug looks approvable in principle.
  • The AbbVie option remains fully alive and is structurally attractive for Aldeyra.
• Bearish camp — points out that:
  • ALDX is still effectively a single-asset trade at this stage.
  • The mixed efficacy history (including the negative primary endpoint in the field trial) does not disappear because of process language.
  • Another negative outcome at the PDUFA date would likely trigger a severe repricing.

7.3. Patient-side emotions

On dry-eye patient boards, the tone is more personal. After years of following reproxalap through multiple PDUFA cycles and Complete Response Letters, there is a mix of frustration about “yet another delay” and cautious hope that the ongoing label discussions mean the drug is at least still under serious consideration.

9. Interpreting the delay — slightly bullish, still honest

If this regulatory chapter were a series, this would not be the episode where the FDA cancels the show. It is the episode where a new supervisor at the agency says:

On the positive side:

• The agency did not issue a new CRL.
• There is no request for a fresh pivotal study.
• Label discussions are active, and the formal letter explicitly talks about next steps in labeling and post-marketing planning if no major deficiencies appear.

On the negative side:

• Investors now live with uncertainty and volatility for at least three more months.
• ALDX remains tightly bound to a single regulatory decision, with past CRLs and mixed efficacy history never far from mind.

Overall, the update is tilted modestly to the constructive side: the review is advanced, the requested CSR has already been scrutinized once, and the big-pharma option remains in play. But nothing about this changes the fundamental reality that ALDX is a binary, high-risk name, and that no approval is ever guaranteed until the action letter is in hand.